Schizophrenia Research
Volume 58, Issue 1 , Pages 63-67 , 1 November 2002

An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder

  • Clare Beasley

      Affiliations

    • Corresponding Author InformationCorresponding author. Section of Experimental Neuropathology and Psychiatry, Institute of Psychiatry, DeCrespigny Park, London SE5 8AF, UK. Tel.: +44-20-7848-0460; fax: +44-20-7848-0051
    • ,
  • David Cotter
    • ,
  • Ian Everall

Received 21 May 2001 ,Accepted 16 October 2001.

References 

  1. Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I, et al. Glycogen synthase kinase-3β immunoreactivity is reduced in the frontal cortex in schizophrenia. Neurosci. Lett. 2001;302:117–120
  2. Brown JD, Moon RT. Wnt signalling: why is everything so negative?. Curr. Opin. Cell Biol. 1998;10:182–187
  3. Cotter D, Kerwin R, Al-Sarraji S, Brion J-P, Chadwich A, Lovestone S, et al. Abnormalities of Wnt signalling in schizophrenia—evidence for neurodevelopmental abnormality. NeuroReport. 1998;9:1379–1383
  4. Coull MA, Lowther S, Katona CLE, Horton RW. Altered brain protein kinase C in depression: a post-mortem study. Eur. Neuropsychopharmacol. 2000;10:283–288
  5. Grove EA, Tole S, Limon J, Yip L, Ragsdale CW. The hem of the embryonic cerebral cortex is defined by the expression of multiple Wnt genes and is compromised in Gli3-deficient mice. Development. 1998;125:2315–2325
  6. Hall AC, Lucas FR, Salinas PC. Axonal remodelling and synaptic differentiation in the cerebellum is regulated by Wnt-7a signalling. Cell. 2000;100:525–535
  7. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 1996;93:8455–8459
  8. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3β immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am. J. Psychiatry. 2000;157:831–833
  9. Kozlovsky N, Belmaker RH, Agam G. Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr. Res. 2001;52:101–105
  10. Kyosseva SV, Elbein AD, Griffin ST, Mrak RE, Lyon M, Karson CN. Mitogen-activated protein kinases in schizophrenia. Biol. Psychiatry. 1999;46:689–696
  11. Lucas FR, Salinas PC. Wnt-7a induces axonal remodelling and increases synapsin I levels in cerebellar neurons. Dev. Biol. 1997;192:31–44
  12. Manji HK, Lenox RH. Signalling: cellular insights into the pathophysiology of bipolar disorder. Biol. Psychiatry. 2000;48:518–530
  13. Manji HK, Chen G, Hsiao JK, Masana MI, Moore GJ, Potter WZ. Regulation of signal transduction pathways by mood-stabilising agents: implications for the pathophysiology and treatment of bipolar affective disorder. In:  Manji HK,  Bowden CL,  Belmaker RH editor. Bipolar Medications: Mechanisms of Action. Washington, DC: American Psychiatric Press; 2000;p. 129–177
  14. Miller JR, Moon RT. Signal transduction through β-catenin and specification of cell fate during embryogenesis. Genes Dev. 1996;10:2527–2539
  15. Miyaoka T, Seno H, Ishino H. Increased expression of Wnt-1 in schizophrenic brains. Schizophr. Res. 1999;38:1–6
  16. Semenov MV, Snyder M. Human dishevelled genes constitute a DHR-containing multigene family. Genomics. 1997;42:302–310
  17. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The Stanley Foundation brain collection and neuropathology consortium. Schizophr. Res. 2000;44:151–155
  18. Wodarz A, Nusse R. Mechanisms of Wnt signalling in development. Annu. Rev. Cell Biol. 1998;14:59–88
  19. Yang SD, Yu JS, Lee TT, Yang CC, Ni MH, Yang YY. Dysfunction of protein kinase FA/GSK-3 alpha in lymphocytes of patients with schizophrenic disorder. J. Cell. Biochem. 1994;5:108–116

PII: S0920-9964(01)00376-0

Schizophrenia Research
Volume 58, Issue 1 , Pages 63-67 , 1 November 2002

Article Tools

* Image Usage & Resolution